Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Change in Working Capital
Apontis Pharma AG
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
Apontis Pharma AG
XETRA:APPH
|
Change in Working Capital
-€3.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
ATAI Life Sciences NV
NASDAQ:ATAI
|
Change in Working Capital
$7.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Bayer AG
XETRA:BAYN
|
Change in Working Capital
-€433m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
![]() |
Merck KGaA
XETRA:MRK
|
Change in Working Capital
-€372m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
![]() |
Dermapharm Holding SE
XETRA:DMP
|
Change in Working Capital
-€92.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
![]() |
PharmaSGP Holding SE
XETRA:PSG
|
Change in Working Capital
-€3.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Change in Working Capital?
Change in Working Capital
-3.4m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Change in Working Capital amounts to -3.4m EUR.